Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637247 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
A Phase 2 study, sponsored by AmpliMed Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT00637247 is a Phase 2 study that has completed, run by AmpliMed Corporation. The registered enrollment target is 142 participants.
The verdict
NCT00637247, a Phase 2 study, has completed, sponsored by AmpliMed Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if imexon in combination with gemcitabine could improve overall survival as compared to gemcitabine alone in subjects with pancreatic cancer that has spread to other organs such as the liver or lungs. The study will also look at the safety of the combination as compared to gemcitabine alone. Participants in the study will be randomly assigned to either treatment and neither the participant or their doctors will know which treatment they will be receiving.
Interventions
- DRUG imexon in combination with gemcitabine
- DRUG imexon placebo + gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637247
The ClinicalTrials.gov registry entry for NCT00637247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AmpliMed Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which imexon in combination with gemcitabine is the first listed.
NCT00637247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637247 about?
NCT00637247 is a clinical study titled "A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer". The purpose of this study is to determine if imexon in combination with gemcitabine could improve overall survival as compared to gemcitabine alone in subjects with pancreatic cancer that has spread to other organs such as the liver or lungs. The study will also look at the safety of the combination...
What is the current status of trial NCT00637247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2008-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00637247?
The interventions under investigation include: imexon in combination with gemcitabine (DRUG), imexon placebo + gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00637247?
This trial is sponsored by AmpliMed Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.